Overexpression of the chemokine receptor CXCR3 and its correlation with favorable prognosis in gastric cancer

Hu, Min; Li, Kai; Maskey, Ninu; Xu, Zhigao; Yu, Fang; Peng, Changhong; Li, Yan; Yang, Guifang

doi:10.1016/j.humpath.2015.08.004

Cited by 34 publications

(39 citation statements)

References 22 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…This notion is in agreement with other findings in gastric cancers, prostate cancer, renal cell carcinoma, ovarian cancers, and colorectal carcinoma . However, these results differed from other findings in gastric cancer and renal cell carcinoma . Hu et al found that an up‐regulated CXCR3A was correlated with a favorable prognosis in gastric cancer, and Klatte et al reported a non‐correlation of the CXCR3 expression and clinicopathological features in renal cell carcinoma, such as TNM stage, vascular invasion.…”

Section: Discussionsupporting

confidence: 86%

“…This notion is in agreement with other findings in gastric cancers, 32 prostate cancer, 6 renal cell carcinoma, 23,42 ovarian cancers, 43 and colorectal carcinoma. 30 However, these results differed from other findings in gastric cancer 35 and renal cell carcinoma. 44 .…”

Section: Discussioncontrasting

confidence: 78%

“…However, these results differed from other findings in gastric cancer and renal cell carcinoma . Hu et al found that an up‐regulated CXCR3A was correlated with a favorable prognosis in gastric cancer, and Klatte et al reported a non‐correlation of the CXCR3 expression and clinicopathological features in renal cell carcinoma, such as TNM stage, vascular invasion. The contradictory roles of CXCR3 in cancer progression may be partially attributed by the binding of different splice isoforms (CXCR3A and CXCR3B) to their ligands other than CXCL9 .…”

Section: Discussionmentioning

confidence: 80%

“…In this regard, CXCR3A and CXCR3B are generally considered to exert opposite functions in cancers, that is, the CXCR3A mediates signals to promote cancer cell proliferation, survival, migration and invasion, and angiostatic effects in tumors; while the CXCR3B induces signaling to suppress cancer cell growth and progression . Therefore, CXCR3 have been recognized as a prognostic marker and a therapeutic target for patients with solid tumors, including gastric cancer, prostate cancer, breast cancer, and the CRC …”

Section: Discussionmentioning

confidence: 99%

“…have been recognized as a prognostic marker and a therapeutic target for patients with solid tumors, 15 including gastric cancer, 32,35 prostate cancer, 6,34 breast cancer, 36 and the CRC. [37][38][39] Indeed, a univariate and multivariate analysis has demonstrated that that the status of CXCR3 protein was an independent prognostic marker for CRC patients, particularly in metastatic CRC.…”

Section: Discussionmentioning

confidence: 99%

See 4 more Smart Citations

Disparate roles of CXCR3A and CXCR3B in regulating progressive properties of colorectal cancer cells

Rong

Chen

et al. 2018

Molecular Carcinogenesis

View full text Add to dashboard Cite

Human C‐X‐C Motif Chemokine Receptor 3A (CXCR3A) and CXCR3B are two splice variants of CXCR3 that is involved in a variety of progressive processes of cancer cells, including proliferation, migration, invasion, and tumorigenicity. However, the molecular mechanisms of CXCR3 in colorectal cancer (CRC) remain incomplete understood. In the present study, a significantly up‐regulated CXCR3 protein was firstly observed in CRC tissues and cell lines in comparison with the paired non‐tumor tissues and normal intestinal epithelial cells, which was positively associated with CRC TNM stages. In contrast, CXCR3B was down‐regulated in CRC tumor tissues compared with that in the corresponding paired paracancerous tissues, and negatively correlated with the TNM stages of cancer. Of interest, the overexpression of CXCR3A enhanced the progressive capacity of cell proliferation, migration, invasion in CRC LOVO and HCT116 cells in vitro, and the tumorigenicity in nude mice in vivo. Conversely, the overexpression of CXCR3B exhibited an opposite phenotype of CXCR3A, with an ability to inhibit the progressive properties in CRC cell lines in vitro and tumorigenesis in vivo. In addition, immunoblotting analysis further demonstrated that an increased expression of CXCR3A inhibited the expression of CXCR3B in CRC cells and NCM460 normal colon epithelial cells; vice verse, an overexpression of CXCR3B suppressed the expression of CXCR3A in these cells. These data imply that an interaction between the CXCR3A and CXCR3B may play an important regulatory role in tumorigenicity of CRC, which warrants for further investigation.

show abstract

Section: Discussionsupporting

confidence: 86%

Section: Discussioncontrasting

confidence: 78%

Section: Discussionmentioning

confidence: 80%

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

See 3 more Smart Citations

Disparate roles of CXCR3A and CXCR3B in regulating progressive properties of colorectal cancer cells

Rong

Chen

et al. 2018

Molecular Carcinogenesis

View full text Add to dashboard Cite

show abstract

Inhibition of CXCL12/CXCR4 axis as a potential targeted therapy of advanced gastric carcinoma

et al. 2017

View full text Add to dashboard Cite

The whole outcome for patients with gastric carcinoma (GC) is very poor because most of them remain metastatic disease during survival even at diagnosis or after surgery. Despite many improvements in multiple strategies of chemotherapy, immunotherapy, and targeted therapy, exploration of novel alternative therapeutic targets is still warranted. Chemokine receptor 4 (CXCR4) and its chemokine ligand 12 (CXCL12) have been identified with significantly elevated levels in various malignancies including GC, which correlates with the survival, proliferation, angiogenesis, and metastasis of tumor cells. Increasing experimental evidence suggests an implication of inhibition of CXCL12/CXCR4 axis as a promising targeted therapy, although there are rare trials focused on the therapeutic efficacy of CXCR4 inhibitors in GC until recently. Therefore, it is reasonable to infer that specific antagonists or antibodies targeting CXCL12/CXCR4 axis alone or combined with chemotherapy will be effective and worthy of further translational studies as a potential treatment strategy in advanced GC.

show abstract

Tamoxifen therapy benefit predictive signature combining with prognostic signature in surgical‐only ER‐positive breast cancer

Jin

Zhang

et al. 2018

Journal Cellular Physiology

View full text Add to dashboard Cite

Tamoxifen treatment is important assistant for estrogen‐receptor‐positive breast cancer (BRCA) after resection. This study aimed to identify signatures for predicting the prognosis of patients with BRCA after tamoxifen treatment. Data of gene‐specific DNA methylation (DM), as well as the corresponding clinical data for the patients with BRCA, were obtained from The Cancer Genome Atlas and followed by systematic bioinformatics analyses. After mapping these DM CPG sites onto genes, we finally obtained 352 relapse‐free survival (RFS) associated DM genes, with which 61,776 gene pairs were combined, including 1,614 gene pairs related to RFS. An 11 gene‐pair signature was identified to cluster the 189 patients with BRCA into the surgical low‐risk group (136 patients) and high‐risk group (53 patients). Then, we further identified a tamoxifen‐predictive signature that could classify surgical high‐risk patients with significant differences on RFS. Combining surgical‐only prognostic signature and tamoxifen‐predictive signature, patients were clustered into surgical‐only low‐risk group, tamoxifen nonbenefit group, and tamoxifen benefit group. In conclusion, we identified that the gene pair PDHA2–APRT could serve as a potential prognostic biomarker for patients with BRCA after tamoxifen treatment.

show abstract

Overexpression of the chemokine receptor CXCR3 and its correlation with favorable prognosis in gastric cancer

Cited by 34 publications

References 22 publications

Disparate roles of CXCR3A and CXCR3B in regulating progressive properties of colorectal cancer cells

Disparate roles of CXCR3A and CXCR3B in regulating progressive properties of colorectal cancer cells

Inhibition of CXCL12/CXCR4 axis as a potential targeted therapy of advanced gastric carcinoma

Tamoxifen therapy benefit predictive signature combining with prognostic signature in surgical‐only ER‐positive breast cancer

Contact Info

Product

Resources

About